A side-by-side look at the peptides most often studied for tissue-repair and recovery research, and what the published literature actually found for each.
BPC-157 is a synthetic 15-amino-acid fragment derived from a protective protein found in human gastric juice. In laboratory and animal research it has been studied mainly for tissue-repair effects, acting through pathways including upregulation of growth hormone receptor expression in tendon fibroblasts, improved cell survival under oxidative stress, and promotion of angiogenesis.
TB-500 is marketed as a synthetic version of a short active region of thymosin beta-4 (Tβ4), a naturally occurring actin-regulating protein studied for roles in cell migration and wound repair. Most published research covers full-length Tβ4 or related fragments rather than the specific synthetic "TB-500" product itself.
This is a combination of two individually studied recovery-research peptides: BPC-157, a synthetic 15-amino-acid fragment derived from a protective protein in human gastric juice, studied for tissue-repair effects including tendon fibroblast migration and angiogenesis; and TB-500, marketed as a synthetic version of a short active region of thymosin beta-4, an actin-regulating protein studied for roles in cell migration and wound repair.
This is a combination of three individually studied research peptides: BPC-157 and TB-500 (see their own research-based tissue-repair literature) alongside GHK-Cu, a naturally occurring copper-binding tripeptide studied for skin remodeling, collagen-related gene expression, and antioxidant activity.
KPV is a tripeptide fragment derived from alpha-melanocyte-stimulating hormone, studied in laboratory and animal models for anti-inflammatory activity in the gut, acting through a transporter-mediated pathway that reduces inflammatory signaling independent of melanocortin receptors.
Thymosin alpha-1 is a synthetic peptide corresponding to a naturally occurring thymic peptide involved in immune regulation, studied for effects on T-cell maturation and function. Much of the clinical research has examined its use as an adjunct immune-modulator in severe infection, administered under medical supervision in hospital settings.
LL-37 is the only cathelicidin antimicrobial peptide produced by humans, a 37-amino-acid fragment of the hCAP-18 precursor protein, studied for direct antimicrobial membrane disruption, anti-biofilm activity, and recruitment of immune cells via formyl peptide receptor signaling.
This guide summarizes published research findings only — it is not medical advice, a dosing recommendation, or a claim about safety or effectiveness for human use. For Research Purposes Only, Not For Human Consumption.